Specifically, we sought to examine whether activation of STING in the thymic stroma using a systemic STING agonist developed for clinical use (for instance, cancer immunotherapy) would phenocopy our findings and promote the output of autoreactive T cell clones. The gene discussed is STING1; the disease is cancer.